產品特色 - 投資目標及策略
世界健康科學基金以盡量提高總回報為目標,並以貫徹環境、 社會及管治(「ESG」)投資原則的方式進行投資。基金將其 至少70%的總資產投資於全球各地主要經濟活動從事保健、 製藥及醫學科技及生物科技供應及開發業務的公司的股本證 券。基金是互聯互通基金,可透過互聯互通機制最多以其總資產 的20%直接投資於中國。
資訊
基金公司 | 成立日期 | 投資市場組別 | 基金類別 | 管理費 | 表現費 | ISIN |
---|---|---|---|---|---|---|
貝萊德資產管理北亞有限公司 | 2001-04-06 | 股票基金 | 行業股票 - 健康護理 | 請參閱 資料單張 | LU0122379950 |
單位價格
資產淨值 | 52週最低-最高價格 |
---|---|
62.83 | 美元 62.83-76.33 |
回報 (%)
累積回報 (%) 截至 2025-04-07 |
年初至今 | 一週 | 一個月 | 三個月 | 六個月 | 一年 | 三年 | 五年 | 十年 | 成立至今 (年化) |
---|---|---|---|---|---|---|---|---|---|---|
基金表現 | -5.28 | -8.94 | -12.70 | -7.06 | -13.46 | -8.05 | -1.78 | 5.66 | 5.65 | 7.96 |
年度化回報 | 2024 | 2023 | 2022 | 2021 | 2020 |
---|---|---|---|---|---|
基金表現 | 1.94 | 2.18 | -5.21 | 14.19 | 13.99 |
MORNINGSTAR 評級
綜合評級 | 三年評級 | 五年評級 | 十年評級 | 截至 |
---|---|---|---|---|
![]() ![]() ![]() ![]() |
![]() ![]() ![]() ![]() |
![]() ![]() ![]() ![]() |
![]() ![]() ![]() ![]() |
2025-03-31 |
基金波幅
一年夏普比率 | 一年標準偏差 | 一年年度化回報率 | 三年夏普比率 | 三年標準偏差 | 三年年度化回報率 | 截至 |
---|---|---|---|---|---|---|
-0.46 | 13.51 | -8.05% | -0.14 | 12.42 | -1.78% | 2025-03-31 |
基金經理 | 基金經理上任日期 | 個人簡介 |
---|---|---|
Liu Xiang | 2020-06-01 | Xiang Liu, PhD, Director, is a member of the Health Sciences team, part of BlackRock’s Active Equity Group. He is co-portfolio manager for the Health Sciences equity portfolios and is responsible for coverage of the medical devices & supplies sector. Prior to joining BlackRock in 2008, Mr. Liu was a partner and biotech analyst at Mehta Partners. From 2002 to 2005, he was a Director in the corporate development department at Cubist Pharmaceuticals. Mr. Liu began his investment career in 2000 at the Boston Consulting Group as a Healthcare consultant. Mr. Liu earned a BS degree in Chemistry from the University of Science & Technology, China in 1993, a PhD degree in Chemistry from Yale University in 1997, and a MBA degree in finance, strategy, and accounting from the University of Chicago in 2000. |
Xie Erin | 2011-04-01 | Erin Xie, PhD, Managing Director and portfolio manager, is the head of the Health Sciences team, part of BlackRock’s Active Equity Group. She is the lead portfolio manager for the Health Sciences equity portfolios. Ms. Xie's service with the firm dates back to 2001, including her years with State Street Research & Management (SSRM), which merged with BlackRock in 2005. At SSRM, she was a Senior Vice President and portfolio manager responsible for managing the State Street Health Sciences Fund. Prior to joining State Street Research in 2001, Ms. Xie was a research associate with Sanford Bernstein covering the pharmaceutical industry from 1999. From 1994 until 1997, she was a post doctoral research scientist at Columbia University. Ms. Xie earned a BS degree in chemistry from Beijing University in 1988, a PhD degree in Biochemistry from the University of California, Los Angeles, in 1993 and a MBA degree from the Massachusetts Institute of Technology Sloan School of Management in 1999. |